The effect of frozen-thawed embryo transfer performed concurrently with hysteroscopy on the reproductive outcomes during assisted reproductive treatments

Xiuxian Zhu, Hongjuan Ye & Yonglun Fu

The uterine environment is vital to the successful conception; recently, hysteroscopy was used to remove uterine anomalies in patients undergoing assisted reproductive treatments in combination with a “freeze-all” strategy. However, the rapid recurrence of uterine anomalies impose a negative impact on pregnancy. A possible way to avoid this issue is to implement frozen-thawed embryo transfer (FET) as soon as possible. Thus, we sought to investigate the impact of performing FET concurrently with hysteroscopy in the same mense on the pregnancy outcome. Patients enrolled were divided into two groups: group 1 (n = 272, FET in this mense) and group 2 (n = 251, FET in the next mense). There were no differences in the clinical pregnancy rate (55.15% vs. 53.78%), implantation rate (39.32% vs. 37.2%), spontaneous miscarriage rate (10% vs. 8.89%), or live birth rate (45.96% vs. 45.02%) when comparing the two groups. Binary logistic regression indicated maternal age was negatively associated with the live birth rate, while FET following hysteroscopy in the same mense had no adverse effects on the live birth rate. Our data indicate performing FET concurrently with hysteroscopy in the same menstrual cycle does not impair the pregnancy outcomes, but additional studies with larger populations are needed to confirm these results.

The embryo quality, uterine environment and a combination of both factors play major roles in achieving and continuing a successful pregnancy outcome for patients undergoing assisted reproductive treatments (ART). Isolated uterine-associated infertility is observed in 2–3% of infertile women, of which intrauterine lesions (40–50%) and endometrial polyps (16–26%) are the most common types of uterine anomalies in these women. These uterine pathologies might result in intracavitary bleeding or an abnormal environment for embryo implantation, leading to compromised spontaneous fertility as well as a reduction in pregnancy rates.

Hysteroscopy is generally considered to be the gold standard in uterine cavity assessment, as it makes the direct visualization of the uterine cavity possible. The abnormal adhesions and polyps could be completely cut off without damaging the adjacent endometrium. Hysteroscopy has the advantages of simplicity, low operative, post-operative complications and high patient tolerance. Endometrial pathology was found in 22.9% of 2,500 patients undergoing hysteroscopic evaluation of the uterine cavity before IVF reported in a large prospective study. It was demonstrated that performing hysteroscopy can increase the chance of pregnancy in the subsequent IVF cycle in women who have had one or more failed IVF cycles. Hysteroscopic removal of endometrial polyps, submucous fibroids, uterine septum or intrauterine adhesions benefit reproduction and fertility, especially for patients recurrent pregnancy losses. Thus, some practitioners recommended a routine hysteroscopy prior to embryo transfer to diagnose and treat such pathologies. Extending the use of hysteroscopy beyond the correction of a uterine pathology was recommended, and this recommendation was corroborated by a recent meta-analysis by Pundir et al., who found a significantly higher clinical pregnancy rate (relative risk (RR) 1.44, 95% CI 1.08–1.92, P = 0.01) and live birth rate (RR 1.30, 95% CI 1.00–1.67, P = 0.05).

Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Rd., Shanghai, 200000, China. Correspondence and requests for materials should be addressed to Y.F. (email: fuyonglunivf@163.com)
However, it is imperative to highlight that uterine anomalies have a high rate of reformation, which has a significant negative impact on the conception rate. The recurrence rate of uterine adhesions after adhesiolysis was identified to be 3.1%–23.5%, and it increased to 20%–62.5% in severe cases. Additionally, studies demonstrated that the postoperative recurrence rates of endometrial polyps ranged from 2.5% to 43.6%. Factors that account for polyp reformation are still obscure. A high E₂ level was proposed to be the highest risk factor. Recently, a multivariate logistic regression analysis, including 168 premenopausal women who suffered from endometrial polyps and underwent hysteroscopic polypectomy, revealed that more endometrial polyps (P = 0.015) and a longer duration of follow-up (P = 0.004) were significantly associated with an increased risk of postoperative polyp recurrence.

In prior decades, hysteroscopy was performed prior to controlled ovarian hyperstimulation (COH) when ART relied on fresh embryo transfer (ET). Patients with severe adhesions needed to wait for two menstrual cycles or more because intrauterine device (IUD) was frequently inserted and a second-look hysteroscopy was performed to removed the recurrent adhesions or endometrial polyps. The improvement of embryo vitrification technology and confirmation of its safety made the “freeze-all” policy emerge as an alternative to fresh ET. In combination with embryo cryopreservation, embryos could be frozen until the uterine environment was suitable for frozen-thawed embryo transfer (FET) and the endometrium could avoid the super-physiological hormone level due to COH. Therefore, it is necessary to explore the optimal time at which to perform hysteroscopic surgery before embryo transfer. Pereira et al. concluded that patients can undergo embryo transfer in the next menses after hysteroscopy without affecting IVF-ET outcomes.

In this study, we sought to investigate the impact of performing FET in the same menstrual cycle after hysteroscopy on reproductive outcomes compared with FET in the following menses.

**Results**

A total of 1,684 patients underwent FET during the study period. Of the 988 patients who underwent hysteroscopy, 523 patients who met the inclusion criteria were grouped as follows: 272 in group 1 and 251 in group 2. Figure 1 summarizes the selection of the study cohort.

Table 1 compares the demographic and baseline IVF characteristics of patients undergoing FET cycles after hysteroscopy. The mean ages of patients in groups 1 and 2 were 29.22 ± 3 and 29.57 ± 2.85 years of age, respectively. As seen with the mean age, there were no significant differences in the mean gravidity, parity or body mass index (BMI) between the two groups in the study cohort. Furthermore, there were no differences in the basal FSH levels or basal E₂ levels at the start of FET. Polyps were found in 82 participants in group 1 compared with 67 in group 2, adhesions were confirmed in 145 patients in group 1 compared with 133 patients in group 2, and combined uterine anomalies were observed in 45 patients in group 1 compared with 51 patients in group 2, with no significant difference. Table 2 compares the pregnancy outcomes of patients undergoing FET cycles after hysteroscopy. An embryo transfer was performed approximately 16.5 ± 8.41 days after hysteroscopy in the study group compared to 39.2 ± 4.72 days in the control group. The mean number of embryos transferred were similar among
the groups. There was no difference in implantation rates (39.32% vs. 37.2%, p > 0.05), clinical pregnancy rates (55.15% vs. 53.78%, p > 0.05), spontaneous miscarriage rates (10% vs. 8.89%, p > 0.05) or live birth rates (45.96% vs. 45.02%, p > 0.05) when comparing the two groups. One-hundred-eleven patients achieved term delivery in the study group, while 100 patients achieved term delivery in the control group, with no significant difference (p > 0.05). The birth weight and gestation week of the single newborns and twin newborns were comparable between the two groups.

Table 3 presents the results of binary logistic regression analyses of related factors on the live-birth rate (live birth = 1). The dependent variables comprised maternal age, infertility duration, BMI, whether FET concurrent with hysteroscopy or not (in the same menses = 1, in the next menses = 0), endometrial thickness and number of transferred embryos, which were included in the analysis using the entry method. The final result showed FET following hysteroscopy in the same menses had no adverse impacts on the live birth rate (OR = 1.022, 95% CI: 0.701–1.492). However, a negative effect of maternal age (OR = 0.936, 95% CI: 0.877–1) was identified on the live birth rate.

**Discussion**

Uterine anomalies, including endometrial fibroids, polyps, adhesions and uterine congenital abnormalities, can result in abnormal uterine bleeding, amenorrhea or hypomenorrhea, infertility or recurrent pregnancy loss. Hysteroscopy provides an accurate visual assessment of the uterine cavity as well as a chance to treat any pathology detected during the examination. The availability of hysteroscopy with smaller diameters has made the use of outpatient or office hysteroscopy feasible as a routine examination.

Several mechanisms were demonstrated in previous studies with regard to endometrial repair after hysteroscopy. First, an inflammatory response may be conducive to the preparation of the endometrium for implantation. Gnainsky et al. collected endometrial samples from women undergoing IVF who had previously failed treatment cycles to determine the abundance of immune cells and the level of cytokines/chemokines. A positive correlation was found between the pregnancy outcome and levels of macrophages/dendritic cells, macrophage inflammatory protein 1B (MIP-1B) expression and tumor necrosis factor-α (TNF-α) expression. These results were corroborated by Junovich et al., who observed that the amount of CD56+ uterine natural killer (NK) cells, a main source of endometrial immunoregulatory cytokines, in the endometrium was reduced by ovarian stimulation, but could be normalized by endometrial injury in the late proliferative phase. Second, endometrial gene expression was altered by hysteroscopic therapy. It was confirmed that the mucin-1 transmembrane, laminin α4, matrix metalloproteinase-1, bladder transmembranal uroplakin IB and phospholipase A2 genes, which were responsible for the regulation of cellular proliferation, differentiation and adhesion, were up-regulated. However, an rapid increase in certain factors harmful to the endometrial regeneration and proliferation, such as side population (SP) progenitor cells, were observed by Hyodo et al. after endometrial injury in a mouse model.

Performing hysteroscopic surgery in patients with intrauterine anomalies diagnosed by HSG or TVS has been accepted as a consensus practice. However, some uterine anomalies are asymptomatic and are prone to be ignored. The prevalence of unsuspected uterine pathology in asymptomatic patients undergoing their first IVF/ICSI treatment varies from 11%–45%. In our study, hysteroscopy was performed prior to embryo transfer in all

| Parameter | FET in this menses (n = 272) | FET in the next menses (n = 251) | P-value |
|-----------|-----------------------------|-------------------------------|---------|
| Age (y)   | 29.22 ± 3                  | 29.57 ± 2.85                 | 0.21    |
| Duration of infertility (years) | 3.26 ± 2.44                | 3.21 ± 2.34                 | 0.627   |
| Gravidity |                             |                              | 0.779   |
| 0         | 176 (64.7%)                | 169 (67.33%)                |         |
| 1–2       | 73 (26.84%)                | 64 (25.5%)                 |         |
| ≥3        | 23 (8.46%)                 | 18 (7.17%)                |         |
| Parity    |                             |                              | 0.781   |
| 0         | 250 (91.91%)              | 229 (91.24%)             |         |
| 1–2       | 22 (8.09%)                | 22 (8.76%)                |         |
| BMI (kg/m²) | 21.87 ± 3.13            | 21.61 ± 3.4            | 0.146   |
| Basal FSH (IU/L) | 5.34 ± 2.2           | 5.45 ± 1.78            | 0.759   |
| Basal E₂ (pg/mL) | 34.95 ± 17.76       | 33.36 ± 12.39         | 0.628   |
| IVF indications |                  |                              | 0.249   |
| Male factor | 29 (10.66%)            | 23 (9.16%)               |         |
| Tubal factor | 132 (48.53%)           | 116 (46.22%)            |         |
| Unexplained infertility | 9 (3.31%)               | 3 (1.19%)               |         |
| Combination of factors | 102 (37.5%)         | 109 (43.43%)           |         |
| Type of uterine anomalies |                  |                              | 0.458   |
| Polyps    | 82 (30.15)                | 67 (26.69%)             |         |
| Adhesions | 145 (53.31%)              | 133 (52.99%)            |         |
| Combined anomalies | 45 (16.54%)          | 51 (20.32%)             |         |
of the participants undergoing their first embryo transfer. Importantly, scissors, instead of electrosurgical methods, were used to dissect adhesions and excise polyps, as was thermal energy in electrosurgery, leading to tissue vaporization, which may impede the repair of the endometrium22.

When should the embryo transfer be implemented after hysteroscopic therapy? Some researchers argue that the short interval between hysteroscopy and embryo transfer may have a negative impact because the endometrium is unable to rapidly regenerate and proliferate. As shown in Karimzade's study, performing endometrial scratching on the day of oocyte retrieval decreased the clinical pregnancy rate23. Nevertheless, it is imperative to highlight that the high rate of recurrent adhesions should be taken into account. Yu et al. analyzed the outcome of hysteroscopic adhesiolysis in 85 women with Asherman's syndrome who presented with a history of infertility or recurrent pregnancy loss. The overall rate of recurrent adhesion was 27.9% at second-look hysteroscopy compared with 41.9% (13 out of 31) in severe cases12. In contrast with only two conceptions in 17 severe cases, 26 conceptions occurred in women with normal cavities after a second-look hysteroscopy. The conception rate was affected by the reformation of adhesions after hysteroscopic adhesiolysis12.

Thus, several researchers maintain that embryo transfer should be performed as soon as possible. Rana et al. divided patients attending an IVF clinic with normal hysteroscopic findings into three groups: hysteroscopy performed 50 days or less before embryo transfer, hysteroscopy between 51 days to 6 months and hysteroscopy at more than 6 months before embryo transfer. The highest pregnancy rate indicated that the endometrium effect was highest when hysteroscopy was performed 50 days or less before embryo transfer1. Pereira et al. suggested performing embryo transfer in the next menses after hysteroscopy15. On the other hand, a retrospective study by Eryilmaz et al. concluded that pregnancy outcomes were unrelated to the time interval, as no significant difference was found in the pregnancy rate between hysteroscopy and the initiation of IVF in 29 and 31 patients who underwent IVF <6 months and >6 months after hysteroscopic polypectomy, respectively24. Broadly speaking, the optimum time to perform hysteroscopic surgery before embryo transfer is far from resolved.

| Parameter | FET in this menses (n = 272) | FET in the next menses (n = 251) | P-value |
|-----------|----------------------------|----------------------------|---------|
| The interval between hysteroscopy and FET (days) | 16.5 ± 8.41 | 39.2 ± 4.72 | <0.001 |
| Thawed embryos (n) | 530 | 493 | |
| Viable embryos after thawed (n) | 529 | 492 | |
| Transferred embryos (n) | 1.93 ± 0.26 | 1.94 ± 0.24 | 0.962 |
| The type of transferred embryos | | | 0.140 |
| No. of cycles with D3 embryos (n) | 262 | 247 | |
| No. of cycles with blastocysts (n) | 10 | 4 | |
| Endometrial preparation (n) | | | 0.389 |
| Natural cycle | 188 | 172 | |
| Mild stimulation | 58 | 62 | |
| Hormone therapy | 26 | 17 | |
| Endometrial thickness (mm) | 11.69 ± 2.85 | 11.58 ± 2.77 | 0.408 |
| Pregnancy outcome of FET (%) | | | |
| Biochemical pregnancy rate per transfer | 62.13% (169/272) | 59.36% (149/251) | 0.517 |
| Clinical pregnancy rate per transfer | 55.15% (150/272) | 53.78% (135/251) | 0.755 |
| Implantation rate | 39.32% (208/529) | 37.2% (183/492) | 0.485 |
| Early miscarriage rate | 10% (15/150) | 8.89% (12/135) | 0.749 |
| Multiple pregnancy rate | 36.67% (55/150) | 35.56% (48/135) | 0.845 |
| Ectopic pregnancy rate | 2.67% (4/150) | 4.44% (6/135) | 0.415 |
| Intrauterine and ectopic pregnancy rate | 0.67% (1/150) | 0 (0/135) | 0.342 |
| Live-birth outcome | | | |
| Live-birth rate per transfer (%) | 45.96% (125/272) | 45.02% (113/251) | 0.830 |
| Term delivery | 111 | 100 | |
| Preterm delivery | 14 | 13 | |
| Late miscarriage | 5 | 4 | |
| Newborns | 73 | 67 | |
| Birth weight (g) | 3,410.6 ± 491.8 | 3,237.35 ± 504.63 | 0.098 |
| Gestational weeks (w) | 39.15 ± 1.05 | 38.7 ± 1.58 | 0.093 |
| Twin newborns (n) | 52 | 46 | |
| Birth weight (g) | 2,544.9 ± 315.31 | 2,625.21 ± 742.93 | 0.134 |
| Gestational weeks (w) | 36.21 ± 1.29 | 36.23 ± 2.2 | 0.193 |

Table 2. Pregnancy outcomes of patients undergoing FET after hysteroscopy.
In conclusion, this study showed that the performance of FET was feasible with hysteroscopy in the same menstrual cycle without impairing pregnancy outcomes. This approach may be especially beneficial for patients who urgently require embryo transfer due to physical or psychological reasons and those who endured reformation of adhesions or polyps in a short time. Further blind randomized controlled trials should be performed to confirm the feasibility of this method, identification of a suitable population, optimal interval and long-term safety of pregnancy and labor.

**Material and Methods**

**Study Setting and Patients.** A retrospective study was conducted at the Department of Assisted Reproduction at the Ninth People's Hospital of Shanghai Jiaotong University School of Medicine. Women undergoing FET cycles after hysteroscopy were recruited from June 2014 to July 2015. The study was conducted according to the Declaration of Helsinki for medical research. Owing to the retrospective nature of the study, individual consent was unnecessary.

The following inclusion criteria were used: 35 years of age or younger; high-quality embryos that were subjected to cryopreservation by vitrification and were still in good condition after being thawed; patients undergoing embryo transfer for the first time; uterine adhesion or polyp discovered by hysteroscopy. All of the hysteroscopies were performed in the follicular phase of the menstrual cycle. Patients received an IUD if a uterine adhesion was found, which often takes two menstrual cycles. The IUD was removed until the uterine environment was found to be normal by the second-look hysteroscopy. Once intrauterine synechia was observed during the second-look hysteroscopy, a repeat adhesiolysis procedure was implemented. Hysteroscopic polypectomy was performed in patients with endometrial polyps. Exclusion criteria included patients with recurrent IVF failure; documented ovarian failure, including a basal FSH level above 10 IU/L or no antral follicles according to ultrasound examination; endometriosis grade 3 or higher; presence of pyosalpinx; or any contraindications to assisted reproductive treatment.

The study group consisted of 272 patients who completed FET in the same menstrual cycle as the hysteroscopy. The control group included 251 patients who finished FET in the next menses after hysteroscopy.

### Table 3. Binary logistic regression of factors related to live-birth rate. OR, odds ratio; CI, confidence interval; P value shows significance of entrance in the logistic regression model; P values in bold indicate statistical significance.

| Variables                          | Coefficient(B) | OR (Exp[B]) (95% CI) | Wald (x²) | P value |
|------------------------------------|-----------------|----------------------|-----------|---------|
| Maternal age (y)                   | −0.066          | 0.936 (0.867–1)      | 3.884     | 0.049   |
| Duration of infertility (y)        | −0.003          | 0.997 (0.919–1.082)  | 0.004     | 0.95    |
| BMI (kg/m²)                        | 0.011           | 1.011 (0.955–1.071)  | 0.14      | 0.708   |
| Whether FET concurrent with hysteroscopy or not | 0.022 | 1.022 (0.701–1.492)  | 0.013     | 0.909   |
| Endometrial thickness (mm)         | 0.025           | 1.025 (0.959–1.096)  | 0.542     | 0.462   |
| No. of transferred embryos (n)     | 0.019           | 1.019 (0.485–2.142)  | 0.003     | 0.96    |
Clinical and Laboratory Protocols. Patients underwent COH using the progesterone protocol as described previously. Briefly, human menopausal gonadotropin (hMG) (Maanshan Pharmaceutical Trading Co., Anhui, China) 150 to 225 IU were administered, concurrently. Utrogestan (Laboratories Besins International, Paris, France) 100 mg twice a day were taken orally from menstrual cycle (MC) day 3–5 until the trigger day. Six days later, a transvaginal ultrasound examination and hormone determination were conducted to monitor the development of follicles. The final stage of oocyte maturation was triggered when there were more than 3 dominant follicles reached 18 mm in diameter, using 0.1 mg triptorelin (Decapeptyl, Ferring Pharmaceuticals, Germany) or 3000 IU human chorionic gonadotrophin (hCG) (Lizhu Pharmaceutical Trading Co., Zuhai, China). Transvaginal ultrasound–guided oocyte retrieval was carried out 34–36 hours after the trigger. All follicles which was more than 10 mm in diameter were picked up.

Based on the specific parameters of semen, in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) was performed to fertilize the aspirated oocytes. On the third day after oocyte retrieval, embryo quality was evaluated according to the number and regularity of blastomeres and the degree of embryonic fragmentation, as stated by Cummins et al., while good-quality embryos defined as embryos with more than 6-cell as well as grade 1 or grade 2, were frozen by vitrification. Only non-top-quality embryos were placed in extended culture until they reached the blastocyst stage. During this stage, only good-morphology blastocysts were frozen on day 5 or day 6.

Endometrium Preparation and FET. For hysteroscopic examination and endometrial mechanical stimulation, the methods and diagnostic criteria followed those published in “Gynecologic Endoscopy” and “Practical Hysteroscopy.”

In this study, embryo and endometrium synchronization with FET was performed via the same methods in the two groups. In brief, natural FET cycles were used for women with regular menstrual cycles, and letrozole was added for patients with irregular menstrual cycles. For patients with thin endometria during either natural cycles or stimulation cycles, hormone treatment was recommended for endometrial preparation. Specifically, red Fematon oral tablets (2 tablets two times per day, including 2 mg micronized estradiol per tablet; Abbott Healthcare Products B.V.) were administered from cycle day 3 onward. After the endometrial lining of each patient was confirmed to be thicker than 8 mm, yellow Fematon tablets were administered orally (2 tablets two times per day, including 2 mg micronized estradiol and 10 mg dydrogesterone per tablet; Abbott Healthcare Products B.V.), and soft vaginal P capsules (200 mg twice per day; Laboratoires Besins International) were also administered. Fematon was designed for sequential therapy for menopausal women, and we used the yellow tablet to initiate secretory changes. The transfer of Day 3 embryos was arranged to be performed 5 days later. The transfer of blastocysts was performed on the fifth day. Once pregnancy was achieved, the exogenous estrogen and P supplements were continued until 10 weeks of gestation.

Outcome Measures. The primary outcome measure was live birth rate. The delivery of a viable infant was considered as the live birth. A biochemical pregnancy was defined as a positive hCG level without a gestational sac. The presence of a gestational sac with or without fetal heart activity, ectopic pregnancy and heterotopic pregnancy were regard as clinical pregnancy, examined at least 7 weeks after FET. The implantation rate was referred to the number of gestational sacs divided by the number of embryos transferred. The miscarriage rate was reckoned as the proportion of patients with a spontaneous termination of pregnancy.

Statistical Analyses. In this study, the data were presented as the means ± SDs, number or percentage. The normality of continuous variables was tested using the Shapiro–Wilk test. The Student’s t-test was applied if the continuous variables were normally distributed; otherwise, the Mann–Whitney U–test was used for the variables of non-normal distribution, and the chi-square test was used for categorical variables. Binary logistic regression was performed to quantify the effect of related factors on the live birth rate. The regression analysis, the possible factors in the model included maternal age, infertility duration, BMI, FET following hysteroscopy in the same cycles or stimulation cycles, hormone treatment was recommended for endometrial preparation. Specifically, red Fematon oral tablets (2 tablets two times per day, including 2 mg micronized estradiol per tablet; Abbott Healthcare Products B.V.) were administered from cycle day 3 onward. After the endometrial lining of each patient was confirmed to be thicker than 8 mm, yellow Fematon tablets were administered orally (2 tablets two times per day, including 2 mg micronized estradiol and 10 mg dydrogesterone per tablet; Abbott Healthcare Products B.V.), and soft vaginal P capsules (200 mg twice per day; Laboratoires Besins International) were also administered. Fematon was designed for sequential therapy for menopausal women, and we used the yellow tablet to initiate secretory changes. The transfer of Day 3 embryos was arranged to be performed 5 days later. The transfer of blastocysts was performed on the fifth day. Once pregnancy was achieved, the exogenous estrogen and P supplements were continued until 10 weeks of gestation.

References
1. Karayalıçın, R. et al. Office hysteroscopy improves pregnancy rates following IVF. Reprod Biomed Online 25, 261–266 (2012).
2. Bosteels, J. et al. Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities. Cochrane Database Syst Rev 31, CD009461 (2013).
3. Taylor, E. & Gomez, V. E. The uterus and fertility. Fertility and Sterility 89, 1–16 (2008).
4. Yang, J. H., Chen, C. D., Chen, S. U., Yang, Y. S. & Chen, M. J. Factors Influencing the Recurrence Potential of Benign Endometrial Polyps after Hysteroscopic Polypectomy. PLoS One 10, e0144857 (2015).
5. Gera, P. S. et al. Role of saline infusion sonography in uterine evaluation before frozen embryo transfer cycle. Fertil Steril 89, 562–566 (2008).
6. El-Touchy, T., Sunkara, S. K., Coomarasamy, A., Grace, J. & Khalaf, Y. Outpatient hysteroscopy and subsequent IVF cycle outcome: a systematic review and meta-analysis. Reprod Biomed Online 16, 712–719 (2008).
7. Karayalıçın, R. et al. Results of 2500 office-based diagnostic hysteroscopies before IVF. Reprod Biomed Online 20, 689–693 (2010).
8. Bosteels, J. et al. The effectiveness of hysteroscopy in improving pregnancy rates in subfertile women without other gynaecological symptoms: a systematic review. Hum Reprod Update 16, 1–11 (2010).
9. Pandir, J., Pandir, V., Osmanwa, K., Khalaf, Y. & El-Touchy, T. Hysteroscopy prior to the first IVF cycle: a systematic review and meta-analysis. Reprod Biomed Online 28, 151–161 (2014).
10. Demirol, A. & Gurgan, T. Effect of treatment of intrauterine pathologies with office hysteroscopy in patients with recurrent IVF failure. Reprod Biomed Online 8, 590–594 (2004).
11. Rama Raju, G. A., Shashi Kumari, G., Krishna, K. M., Prakash, G. J. & Madan, K. Assessment of uterine cavity by hysteroscopy in assisted reproduction programme and its influence on pregnancy outcome. Arch Gynecol Obstet 274, 160–164 (2006).
12. Yu, D. et al. Factors affecting reproductive outcome of hysteroscopic adhesiolysis for Asherman’s syndrome. Fertil Steril 89, 715–722 (2008).
13. Ozgur, K., Berkkanoglu, M., Bulut, H., Isikli, A. & Coetzee, K. Higher clinical pregnancy rates from frozen-thawed blastocyst transfers compared to fresh blastocyst transfers: a retrospective matched-cohort study. J Assist Reprod Genet 32, 1483–1490 (2015).
14. Ozgur, K., Berkkanoglu, M., Bulut, H., Humaidan, P. & Coetzee, K. Perinatal outcomes after fresh versus vitrified-warmed blastocyst transfer – a retrospective analysis. Fertil Steril 104, 899–907 (2015).
15. Pereira, N. et al. Does the time interval between hysteroscopic polypectomy and start of in vitro fertilization affect outcomes? Fertil Steril 105, 539–544 (2016).
16. Gnaninsky, V. et al. Local injury of the endometrium induces an inflammatory response that promotes successful implantation. Fertil Steril 94, 2030–2036 (2010).
17. Junovich, G. et al. Ovarian stimulation affects the levels of regulatory endometrial NK cells and angiogenic cytokine VEGF. Am J Reprod Immunol 65, 146–153 (2011).
18. Zhou, L., Li, R., Wang, R., Huang, H. X. & Zhong, K. Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates. Fertil Steril 89, 1166–1176 (2008).
19. Chen, S. L. et al. Combined analysis of endometrial thickness and pattern in predicting outcome of in vitro fertilization and embryo transfer: a retrospective cohort study. Reprod Biol Endocrinol 8, 30 (2010).
20. Hyodo, S., Matsubara, K., Kameda, K. & Matsubara, Y. Endometrial injury increases side population cells in the uterine endometrium: a decisive role of estrogen. Tohoku J Exp Med 224, 47–55 (2011).
21. Fatemi, H. M. et al. Prevalence of unsuspected uterine cavity abnormalities diagnosed by office hysteroscopy prior to in vitro fertilization. Hum Reprod 25, 1959–1965 (2010).
22. Fabuccu, R. et al. Efficiency and pregnancy outcome of serial intrauterine device-guided hysteroscopic adhesiolysis of intrauterine synechiae. Fertil Steril 90, 1973–1977 (2008).
23. Karimzade, M. A., Oskouian, H., Ahmadi, S. & Oskouian, L. Local injury to the endometrium on the day of oocyte retrieval has a negative impact on implantation in assisted reproductive cycles: a randomized controlled trial. Arch Gynecol Obstet 301, 499–503 (2010).
24. Eryilmaz, O. G. et al. Appropriate interval between endometrial polyp resection and the proceeding IVF start. Arch Gynecol Obstet 685, 1753–1757 (2012).
25. Guven, S. et al. Endometrial injury may increase the clinical pregnancy rate in normal responders undergoing long agonist protocol ICSI cycles with single embryo transfer. Eur J Obstet Gynecol Reprod Biol 173, 58–62 (2014).
26. Li, L. et al. Effect of curettage and copper wire on rabbit endometrium: a novel rabbit model of endometrial mechanical injury. Chin Med J (Engl) 124, 1708–1713 (2011).
27. Dreisler, E., Stampe Sorensen, S., Ibsen, P. H. & Loss, G. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20–74 years. Ultrasound Obstet Gynecol 33, 102–108 (2009).
28. Zhu, X. et al. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine (Baltimore) 94, e909 (2015).
29. Cummins, J. M. et al. A formula for scoring human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality. J In Vitro Fert Embryo Transf 3, 284–295 (1986).
30. Zhang, X. L. et al. Clinical observations of sequential therapy with Chinese medicine and hysteroscopic mechanical stimulation of the endometrium in infertile patients with repeated implantation failure undergoing frozen-thawed embryo transfer. Chin J Integr Med 21, 249–253 (2015).

Acknowledgements
This study was funded by the Natural Science Foundation of Shanghai 17411963700 and the National Nature Science Foundation of China (grant number: 81601344). We thank all the staff of the Department of Assisted Reproduction in Shanghai Ninth People’s hospital for their support for this trial.

Author Contributions
H.J.Y. collected the data; X.X.Z. designed the study and wrote the first draft of the manuscript; Y.I.F. selected studies for inclusion and revised the manuscript.

Additional Information
Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017